Artal Group’s Vor Biopharma VOR Stock Holding History

Artal Group’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-50,000	Closed	-$2.37M	–	130
2024 Q1	$2.37M	Sell	50,000 -67,371	-57%	-$2.96M	0.06%	80
2023 Q4	$5.28M	Sell	117,371 -17,030	-13%	-$703K	0.18%	49
2023 Q3	$5.7M	Hold	134,401	–	–	0.24%	56
2023 Q2	$8.31M	Sell	134,401 -5,239	-4%	-$478K	0.26%	55
2023 Q1	$15M	Sell	139,640 -4,139	-3%	-$459K	0.89%	28
2022 Q4	$19.1M	Buy	143,779 +116,279	+423%	+$11.5M	1.07%	32
2022 Q3	$2.19M	Hold	27,500	–	–	0.09%	93
2022 Q2	$2.73M	Hold	27,500	–	–	0.15%	85
2022 Q1	$3.32M	Hold	27,500	–	–	0.14%	97
2021 Q4	$6.39M	Hold	27,500	–	–	0.17%	89
2021 Q3	$8.62M	Hold	27,500	–	–	0.19%	86
2021 Q2	$10.3M	Hold	27,500	–	–	0.21%	88
2021 Q1	$23.7M	Buy	+27,500	New	+$23.3M	0.42%	53

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group's VOR Position: Q2 2024 in Review

Artal Group sold out of Vor Biopharma (VOR) in Q2 2024, closing a stake of 50,000 shares — an estimated $2.37M sold.

Artal Group first reported a position in VOR in Q1 2021 and held it in 13 quarters. The position peaked at $23.7M in Q1 2021. 71 funds tracked by Wall St. Rank hold VOR as of Q2 2024.

Artal Group reported no remaining Vor Biopharma position as of Q2 2024 after selling out during the quarter.
Artal Group sold 50,000 Vor Biopharma shares in Q2 2024, an estimated $2.37M.
Artal Group first reported a position in Vor Biopharma in Q1 2021 and held it in 13 quarters.
Artal Group's Vor Biopharma position peaked at $23.7M in Q1 2021.
71 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2024.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.